Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients

Cirino Botta, Ignazio Martellucci, Danilo Rocco, Cirino Botta, Domenico Ciliberto, Pierpaolo Pastina, Nicoletta Staropoli, Giulia Marvaso, Annamaria Guglielmo, Antonio Rossi, Pasquale Sperlongano, Rafaele Addeo, Vito Barbieri, Pierpaolo Correale, Michele Caraglia, Pierfrancesco Tassone, Luigi Pirtoli, Pierosandro Tagliaferri, Cesare Gridelli

Risultato della ricerca: Articlepeer review

64 Citazioni (Scopus)

Abstract

Bevacizumab is a humanized anti-VeGF monoclonal antibody able to produce clinical beneit in advanced non-squamous non-small cell lung cancer (nsCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or biological markers have been identiied and validated for baseline patient selection. preclinical indings suggest an important role for myeloid-derived inlammatory cells, such as neutrophils and monocytes, in the development of VeGF-independent angiogenesis. We conducted a retrospective analysis to investigate the role of peripheral blood cells count and of an inlammatory index, the neutrophil-tolymphocyte ratio (nLR), as predictors of clinical outcome in nsCLC patients treated with bevacizumab plus chemotherapy. one hundred twelve nsCLC patients treated with chemotherapy ± bevacizumab were retrospectively evaluated for the predictive value of clinical or laboratory parameters correlated with inlammatory status. Univariate analysis revealed that a high number of circulating neutrophils and monocytes as well as a high nLR were associated with shorter progression-free survival (pFs) and overall survival (os) in bevacizumab-treated patients only. We have thus developed a model based on the absence or the presence of at least one of the above-mentioned inlammatory parameters. We found that the absence of all variables strongly correlated with longer pFs and os (9.0 vs. 7.0 mo, hR: 0.39, p = 0.002; and 20.0 vs. 12.0 mo, hR: 0.29, p < 0.001 respectively) only in nsCLC patients treated with bevacizumab plus chemotherapy. our results suggest that a baseline systemic inlammatory status is marker of resistance to bevacizumab treatment in nsCLC patients. © 2013 Landes Bioscience.
Lingua originaleEnglish
pagine (da-a)469-475
Numero di pagine7
RivistaCANCER BIOLOGY & THERAPY
Volume14
Stato di pubblicazionePublished - 2013

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.1300.1313???
  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.3000.3004???
  • ???subjectarea.asjc.1300.1306???

Fingerprint

Entra nei temi di ricerca di 'Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients'. Insieme formano una fingerprint unica.

Cita questo